RxDoctor Payments Data

Rachel Bowers, PA

Medical · Las Vegas, NVNPI 1093743510

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.6% of it on its own, with 41 other manufacturers making up the rest. Among medical clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,608in general payments, 2019–2025

Across 474 payments — averaging $60.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • Astellas Pharma US Inc$1K
  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$1K
  • Dendreon Pharmaceuticals LLC$641
  • Urogen Pharma, Inc.$417
  • plus $4K from 36 others
$210in research payments, 2019–2025

Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$210

What the payments were for

  • Speaking & faculty fees$15,15053%
  • Travel & lodging$3,60513%
  • Food & beverage$9,36833%
  • Education$4852%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,608 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$102,203
Medicare patients
272
Services billed
8,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron208$171,971
GemtesaVibegron71$59,419
Estradiol389$20,232
Methenamine Hippurate126$9,767
Solifenacin Succinate251$8,646
ProgesteroneProgesterone, Micronized111$4,214
Testosterone Cypionate44$3,313
Tamsulosin Hcl186$2,709
YuvafemEstradiol16$2,594
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$2,199
Oxybutynin Chloride ErOxybutynin Chloride91$1,493
Cefdinir42$945
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$655
Alfuzosin Hcl ErAlfuzosin Hcl32$588
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,474$171,971208 claims
Sumitomo Pharma America, Inc.Gemtesa$1,101$59,41971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.

Other medical in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →